Melanotan II (MT-II) is one of the most widely researched cosmetic peptides. It is also one where the side effect profile requires serious discussion and careful consideration.
What Melanotan II does:
MT-II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It activates melanocortin receptors, primarily MC1R (responsible for melanin production) and MC4R (involved in appetite and sexual function). The result is increased melanin production — skin tans without UV exposure, or tans significantly faster and deeper with minimal UV exposure.
Standard research protocol:
Loading phase: 0.25-0.5mg subcutaneous injection daily for 2-4 weeks, combined with moderate UV exposure (10-15 minutes of sun or a few minutes in a tanning bed) 2-3 times per week. UV exposure is necessary to activate the melanin that MT-II stimulates production of.
Maintenance: Once desired pigmentation is reached, frequency drops to 0.5mg once or twice weekly with occasional UV exposure to maintain.
Side effects — preparation is essential:
Nausea is extremely common, especially during the loading phase. Most researchers report it subsides after the first week. Injecting before bed allows sleep through the worst of it. Starting at 0.25mg and titrating up reduces severity.
Facial flushing — temporary redness and warmth in the face for 1-2 hours after injection. Harmless but noticeable.
Appetite suppression — MC4R activation reduces hunger. Some researchers view this as a benefit; others find it problematic.
Increased libido — also MC4R mediated. This is dose-dependent and can be significant. In men, spontaneous erections can occur and last uncomfortably long at higher doses. Priapism (prolonged erection) is a medical emergency that requires immediate attention.
New mole formation and darkening of existing moles — this is the most important side effect to monitor. MT-II increases melanocyte activity across the entire body. New moles, freckles, and darkening of existing spots should be monitored carefully. Any mole that changes shape, becomes asymmetric, or develops irregular borders should be evaluated by a dermatologist. This is non-negotiable.
The melanoma concern:
This requires direct discussion. There is ongoing debate about whether MT-II could promote melanoma in susceptible individuals. The reasoning: melanocytes are the cells that become malignant in melanoma, and MT-II stimulates melanocyte activity. While no causal link has been established in human research, the theoretical concern is legitimate. Researchers with a personal or family history of melanoma should weigh this carefully. Regular dermatological monitoring (skin checks) is strongly recommended for anyone researching MT-II.
Practical tips from the research community:
Starting low — 0.25mg is enough for most researchers to assess tolerance. Injecting before bed allows sleep through the nausea. Combining with only moderate UV is important — significantly less sun exposure is needed compared to natural tanning. Natural skin tone affects loading requirements — fair-skinned individuals may need a longer loading phase. Staying hydrated is important — dehydration makes nausea worse. Documenting mole changes with photos at consistent intervals provides important baseline data.
This is a peptide where informed consent about the risks is especially important. The cosmetic results can be dramatic, but the side effect profile demands awareness and careful monitoring.
